New hope for tough blood cancers: first patients test experimental drug
NCT ID NCT06708897
Summary
This is the first study in people testing a new drug called ZE50-0134 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Norton Cancer Institute, St. Matthews Campus
RECRUITINGLouisville, Kentucky, 40207, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45221, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.